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Background: Adverse drug events (ADE) occur frequently during treatment with vitamin K 
antagonists (AVK) and contribute to increase hemorrhagic risks.
Methods: A retrospective study was conducted over a period of 2 years. Patients treated with 
AVK and admitted to the emergency room of a tertiary care hospital in Beirut were included. 
The aim of the study was to identify ADE characterized by a high international normalized ratio 
(INR) and to determine the predictive factors responsible for these events. Statistical analysis 
was performed with the SPSS statistical package.
Results: We included 148 patients. Sixty-seven patients (47.3%) with an INR above the 
therapeutic range were identified as cases. The control group consisted of 81 patients (54.7%) 
with an INR within the therapeutic range. Hemorrhagic complications were observed in 53.7% of 
cases versus 6.2% of controls (P , 0.0001). No significant difference was noticed between cases 
and controls regarding the indication and the dose of AVK. Patients aged over 75 years were 
more likely to present an INR above the therapeutic range (58.2%, P = 0.049). Recent infection 
was present in 40.3% of cases versus 6.2% of controls (P , 0.0001) and hypoalbuminemia in 
37.3% of cases versus 6.1% of controls (P , 0.0001). Treatment with antibiotics, amiodarone, 
and anti-inflammatory drugs were also factors of imbalance (P , 0.0001).
Conclusion: Many factors may be associated with ADE related to AVK. Monitoring of INR 
and its stabilization in the therapeutic range are important for preventing these events.
Keywords: adverse drug events, vitamin K antagonists, bleeding risks, therapeutic 
imbalance
Vitamin K antagonists (AVK) have been shown to be an effective preventive or 
therapeutic strategy for arterial and venous thromboembolism. About 1% of the French 
population is currently treated with AVK.1 In the Western world approximately 15 to 
20 per 1000 subjects use AVK, and this number is increasing, probably due to aging 
of the population and increasing adherence to guidelines.2 An important complication 
of treatment with these agents is hemorrhage, which may be life threatening. In France 
there are 17,000 hospitalizations per year for AVK-related bleeding events.3 The ENEIS 
study showed that AVK are responsible for almost 50% of the serious adverse events 
caused by anticoagulants and about 17% of the total serious adverse drug reactions 
that are more often the result of therapeutic errors, such as inadequate prescription or 
administration, inappropriate monitoring, absence of treatment resulting from poor 
adherence, or absence of prescription or administration.4 A study carried out at Beirut 
Governmental Hospital, Lebanon, showed that anticoagulants were responsible for 
7.4% of adverse drug events.5 Among 101 hospitalized patients with major bleeding, 
50 patients had excessive anticoagulation and the overall mortality at 60 days was 
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26% (increased effect was seen with the group using AVK 
versus other anticoagulants). As a result, excessive AVK 
therapy was a significant predictor of mortality as well as 
morbidity.6
The French Society of Clinical Pharmacy defines an 
adverse drug event (ADE) as an injury occurring during the 
patients’ drug therapy, whether resulting from appropriate 
care or from unsuitable or suboptimum care.7
The goal of our study was to identify ADE characterized 
by a high value of international normalized ratio (INR) and 
to determine the predictive factors of therapeutic imbalance 
responsible for these accidents.
Patients and methods
We conducted a retrospective study of patients who were 
hospitalized at Beirut Governmental Hospital, Lebanon, and 
treated with AVK between March 1, 2009 and February 28, 2011. 
Inclusion criteria were an age of 18-years old or more and an INR 
within or higher than the therapeutic range. The cases consisted 
of patients who had an INR above the therapeutic range while 
using AVK, while the control group consisted of patients having 
their INR within the therapeutic range while using AVK.
Selection of patients was done using the computerized patient 
files. These files were used in order to retrieve the necessary 
information for the study. The research support was a questionnaire 
completed for each patient and composed of three parts:
•	 One part related to patient and treatment characteristics, 
including age, sex, alcohol consumption, smoking status, 
past medical history of the patient, prescribed mole  cule, 
indication, dose and frequency of administration, labora-
tory data at admission (INR, levels of hemoglobin, plate-
lets, albumin). The dose was considered as the daily intake 
of AVK (mg/day). INR higher than the therapeutic range 
or within the therapeutic range was based on the recom-
mendations of Agence Française de Sécurité Sanitaire des 
Produits de Santé (AFSSAPS).8 Low hemoglobin count 
was defined as a level of hemoglobin below 13.5 g/dL in 
males or 12 g/dL in females; low hematocrit as a hemato-
crit count below 41% in males or 36% in females; low 
platelet level as a platelet count below 150,000/mm;3 high 
creatininemia as a creatinine level above 1.2 mg/dL; and 
hypoalbuminemia as an albumin level below 3.5 g/dL.9
•	 One part related to health care professionals who pre-
scribed or dispensed the drug, including
–	   prescribing without taking into consideration the 
medical history of the patient: presence of absolute or 
relative contraindications to AVK therapy according 
to AFSSAPS.10
–	   presence of drug–drug interactions: Presence of drug 
interactions was defined when a precaution for use is 
recommended, the drug interaction should be taken 
into account or the use of one or more drugs is dis-
couraged or contraindicated. Drug interactions were 
evaluated according to the Thesaurus des interactions 
médicamenteuses.11
•	 One part related to bleeding signs and management of 
bleeding or nonbleeding patients with a high INR: For all 
patients, signs of hemorrhage and internal bleeding were 
indicated, such as epistaxis, gastrointestinal bleeding, 
intracranial hemorrhage, hematuria, melena, hematoma, 
palpitations, syncope, or fatigue. Possible treatment strat-
egies in the management of a high INR included in our 
questionnaire were those recommended by AFSSAPS, 
such as INR monitoring, withholding AVK, withholding 
any other drug supposed to interact with the AVK and 
cause this bleeding, administering vitamin K, transfusion 
of fresh frozen plasma, restoration of red blood cell mass, 
and transfusion of pooled plasma products.12
Statistical analysis
Comparison of ordinal variables between cases and control 
groups was evaluated using the Chi-square test. For all statistical 
tests, P , 0.05 was considered statistically significant. We also 
used multivariate logistic regression modeling to determine 
the impact of multiple factors of imbalance (independent 
variables) presented simultaneously to predict the dependent 
variable, which was an INR higher than the therapeutic range. 
Prior to model fitting, a matrix correlation analysis was utilized 
to evaluate the relationship between the dependent variables 
and investigate any potential collinearity. In the event of 
significant collinearity (ie, r . 0.7) between two variables, only 
one of the two variables was chosen and was reported in the 
analysis. Statistical analysis was performed using SPSS version 
17 (IBM Corporation, Armonk, NY, USA).
Results
We included 148 patients (67 [45.3%] cases and 81 [54.7%] 
controls) using AVK in our study.
Characteristics of patients on AVK 
treatment
Fifty-eight percent of the cases were over 75-years old versus 
40.7% of the controls (P = 0.049). Characteristics of cases 
and controls for which significant differences between the two 
groups were found are shown in Table 1. Twenty-seven of the 
cases (40.3%) developed an infection prior to their admission 
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versus 6% of the controls (P , 0.0001). Significant differences 
between the two groups were observed when comparing low 
levels of hemoglobin (P , 0.0001), low levels of albumin 
(P , 0.0001), and high creatininemia (P = 0.002).
Comparison of drug–drug interactions 
between cases and controls
A drug–drug interaction was observed in 91% of the 
cases versus 77.7% of the controls (P = 0.029); 35.8% 
of the cases were on antibiotic therapy versus 11% of the 
controls (P , 0.0001). Most of these drug–drug interactions 
required precaution for use. The antibiotics of most concern 
were penicillins (P = 0.039) and quinolones (P = 0.031). 
Significant differences were shown with concomitant use 
of anti-inflammatory drugs (P , 0.0001), anticoagulants or 
antiplatelet agents (P = 0.002), and amiodarone (P , 0.0001) 
(Table 2).
Comparison of signs of bleeding between 
cases and controls
Thirty-six of the cases developed a hemorrhage (53%) 
versus 6% of the controls (P , 0.0001). Hematuria, hematoma, 
intracranial bleeding, and decreased levels of hemoglobin 
were predominant among patients showing a high INR. 
Other signs of hemorrhage, such as melena, hemoptysis, and 
epistaxis, were not significantly associated with an INR level 
above the therapeutic range. In contrast, a significant difference 
was seen when comparing signs of internal bleeding, such as 
fatigue, pallor, palpitations, syncope, and dizziness, between 
cases and controls (Table 3).
Management of bleeding or nonbleeding 
patients with high iNR values
Management of bleeding or nonbleeding patients with a 
high INR was individualized depending on the severity, 
localization of the hemorrhage, and the INR value. INR 
monitoring was carried out for 34.5% of the patients, while 
18.2% of the patients received oral vitamin K (Figure 1).
Multivariate logistic regression coefficient 
for iNR higher than the therapeutic range
Multivariate logistic regression analysis used to quantify the 
relationship between these risk factors and the occurrence of 
ADE characterized by a high INR showed that a drug–drug 
Table 2 Comparison of drug–drug interactions between cases and controls
Variables Cases (n = 67) Controls (n = 81) P*
Drug–drug interaction 61 (91%) 63 (77.7%) 0.029
  Contraindication 1 (1.49%) 1 (1.23%) 0.892
  Discouraged 10 (14.9) 15 (18.5%) 0.561
  Precaution for use 60 (89.5%) 61 (75.3%) 0.026
  Take into account 1 (1.49%) 0 (0%) 0.361
Antibiotics 24 (35.8%) 9 (11.1%) ,0.0001
Penicillins 10 (14.9%) 4 (4.9%) 0.039
Quinolones 9 (13.4%) 3 (3.7%) 0.031
Anti-inflammatory drugs 18 (26.8%) 1 (1.2%) ,0.0001
Paracetamol 1 (1.5%) 5 (6.1%) 0.056
Antifungals 5 (7.5%) 3 (3.7%) 0.324
Statins 18 (28.9%) 22 (27%) 0.986
Anticoagulants/antiplatelet agents 32 (47.7%) 20 (24.7%) 0.002
Aspirin 10 (14.9%) 2 (2.5%) 0.006
Amiodarone 19 (28.3%) 3 (3.7%) ,0.0001
Note: *Chi-square test used.
Table 1 Characteristics of patients on treatment with vitamin K antagonists
Variables Cases (n = 67) Controls (n = 81) P*
Age over 75 years 39 (58.2%) 33 (40.7%) 0.049
Recent infection 27 (40.3%) 5 (6.2%) ,0.0001
Hypertension 52 (77.6%) 51 (62.9%) 0.054
Low level of hemoglobin 48 (71.6%) 19 (23.5%) ,0.0001
Low albumin 25 (37.3%) 5 (6.1%) ,0.0001
High creatininemia 32 (47.7%) 20 (24.7%) 0.002
Note: *Chi-square test used.
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interaction increased by sixfold the probability of having an 
INR higher than the therapeutic range (P = 0.0065). This 
probability was twice the value when a recent infection 
was present (P = 0.003), five times higher when there was 
concomitant use of aspirin (P = 0.0074), five times higher 
when there was concomitant use of amiodarone (P = 0.008), 
and 4.5 times higher in the case of hypoalbuminemia 
(P = 0.0005) (Table 4).
Discussion
The risk of having an INR above the therapeutic range 
during AVK therapy was higher in patients over 75 years 
of age (P = 0.049). Similar results were found in a study 
that evaluated the relationship of age and other risk 
factors to the incidence of major bleeding during warfarin 
therapy.13 Major bleeding occurred more frequently in 
patients . 75 years of age (5.1% annually) than in younger 
patients (1% annually), and multivariate analysis indicated 
that age . 75 years was the only variable independently 
related to primary bleeding during warfarin therapy (bleeding 
unrelated to organic lesion).13 The mechanism of how aging 
causes anticoagulant-related bleeding is not known, but the 
elderly are the major users of AVK because the two most 
common indications for such treatment, atrial fibrillation 
and venous thromboembolism, are most prevalent in the 
elderly.14 Another study suggested that older individuals are 
at a greater risk of bleeding than their younger counterparts 
with similar diagnoses because of increasing comorbidities.15 
Age is not directly responsible for increased risk of bleeding; 
correlates of aging, such as comorbidities and polypharmacy, 
may be the culprits. No gender differences were found 
between patients who showed an INR above therapeutic 
Table 3 Comparison of signs of bleeding between cases and controls
Variables Cases (n = 67) Controls (n = 81) P*
Hemorrhage 36 (53%) 5 (6.2%) ,0.0001
  Hematuria 18 (27%) 3 (3.7%) ,0.0001
  Hematoma 10 (15%) 0 (0%) ,0.0001
  intracranial bleeding 4 (5.9%) 0 (0%) 0.026
  Decreased hemoglobin level 15 (22%) 2 (2.5%) ,0.0001
internal bleeding 30 (45%) 1 (1.2%) ,0.0001
  Fatigue 13 (19%) 1 (1.2%) ,0.0001
  Pallor 9 (13%) 1 (1.2%) 0.003
  Palpitations 6 (8.9%) 1 (1.2%) 0.018
  Syncope 7 (10%) 0 (0%) 0.003
  Dizziness 7 (8.6%) 1 (1.5%) 0.014
Note: *Chi-square test used.
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Figure 1 Management of bleeding or nonbleeding patients with a high iNR. 
Abbreviations: iNR, international normalized ratio; AVK, vitamin K antagonists; FFP, fresh frozen plasma.
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range and those who showed a normal INR. A comparison 
with observational studies enrolling patients with various 
indications for AVK showed that our findings were similar. 
No significant difference in bleeding rate was found between 
males and females.16 However, a univariate analysis indicated 
a higher frequency of major bleeding in females treated for 
atrial fibrillation.13
Patient-related factors, such as comorbidity and state 
of disease, may represent other significant risk factors for 
therapeutic imbalance during AVK treatment. In our study 
only a history of recent infection seemed to be significantly 
related to an INR higher than the therapeutic range 
(P , 0.0001). Our results were similar to those of a case-
control study conducted in order to study the risk factors for 
a high INR range with or without bleeding complications; 
a significant association was found between the presence 
of an infectious disease or a fever and the occurrence of 
a hemorrhagic stroke (odds ratio [OR] = 6; P = 0.007).17 
Our interpretation is that infectious diseases require the 
use of antibiotics, which cause decreased production of 
vitamin K by intestinal flora and increased sensitivity to 
AVK. Increased catabolism of vitamin K-dependent clotting 
factors can be found in hypermetabolic states, such as 
fever, and an increased intake of nonsteroidal inflammatory 
drugs, frequently prescribed in the case of fever, may also 
increase the anticoagulant effect.18 Monitoring INR should 
be increased in these high-risk situations.
Other comorbidities, such as high creatininemia, were 
significantly associated with an INR above the therapeutic 
range. A recent analysis of a clinical trial on treatment 
of patients with atrial fibrillation (the Atrial Fibrillation 
Follow-up Investigation of Rhythm Management [AFFIRM] 
study) reported that congestive heart failure, hepatic or 
renal disease, and diabetes were conditions, among others, 
significantly associated with major bleeding.19 Other 
studies showed that a history of bleeding (especially in 
the gastrointestinal tract) is the patient-related factor most 
frequently reported to be predictive for a risk of further 
bleeding complications,20 and that liver diseases potentiate 
the response to AVK by impairing synthesis of coagulation 
factors and usually make control of anticoagulation more 
difficult. In a recent review,21 a history of bleeding, history 
of myocardial infarction, and previous cerebrovascular 
events were all factors associated with a higher risk of 
bleeding complications. Blood pressure was a critical factor 
for bleeding complications during AVK therapy in some,22 
though not all, studies.23
Clinical factors, such as low hemoglobin, were found to 
be highly associated with an INR above the therapeutic range 
(P , 0.0001), and a low hemoglobin level is an indicator 
of ongoing hemorrhage occurring in patients with an INR 
above the therapeutic range. Hypoalbuminemia was also 
significantly associated with an INR above the therapeutic 
range (P , 0.0001). AVK are highly bound to plasma 
proteins, primarily to albumin, and hypoalbuminemia may 
increase the free fraction of AVK, leading to an enhanced 
anticoagulant effect. Our findings were similar to those of 
a retrospective study in which 30.2% of the cases with a 
high INR suffered from protein malnutrition.24 In contrast, 
a prospective evaluation of an index for predicting major 
bleeding in outpatients treated with warfarin showed that 
bleeding risk associated with warfarin therapy can be 
estimated by elevated serum creatinine . 1.5 mg/dL and 
hematocrit , 30%.25
Treatment-related factors, such as the prescribed molecule, 
dose, and the pathology which led to AVK treatment, were not 
factors of therapeutic imbalance in our study. However, the 
majority (98%) of patients were treated with acenocoumarol, 
while only 2% used warfarin since warfarin was withdrawn 
from the market in 1999; this made it difficult to find any 
association between the type of prescribed molecule and a 
high INR. A previous study comparing acenocoumarol with 
warfarin in a group of 103 patients who were treated with 
acenocoumarol and then changed to warfarin showed that 
warfarin did not appear to be better than acenocoumarol 
for anticoagulation in terms of INR within the therapeutic 
range per patient.26 The majority of patients included in our 
study (80%) were taking 0.5 to 3 mg of acenocoumarol 
once daily (less than one tablet of Sintrom 4 mg). This dose 
was determined based on the relatively older population in 
our study, and thus we found no significant dose-related 
association. A study showed an increased risk of hemorrhage 
under AVK treatment when the dose of AVK was higher than 
that recommended.27 No significant association was found 
between values of INR above the therapeutic range and the 
type of pathology that leads to AVK treatment. Our results 
Table 4 Logistic regression coefficient for values of INR higher 
than the therapeutic range
Variables P ORa [95% CI]
Recent infection 0.003 1.76 [2.77–27.67]
Low level of albumin 0.0005 4.50 [1.76–8.08]
Concomitant use of amiodarone 0.008 4.73 [1.18–5.23]
Concomitant use of aspirin 0.0074 5.20 [1.78–6.35]
Presence of drug–drug interactions 0.0065 5.70 [0.45–5.67]
Abbreviations: iNR, international normalized ratio; ORa, adjusted Odds Ratio; 
CI, confidence interval.
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were similar to a study on whether AVK treatment influences 
bleeding risk; no difference between bleeding risks was seen 
between patients treated for venous thromboembolism or 
atrial fibrillation.28
Another factor of therapeutic imbalance found in our 
study was the use of concomitant medications (P = 0.029). 
This involved antibiotics (P , 0.0001), mainly penicillins 
and quinolones (P = 0.039 and P = 0.031, respectively). 
Anti-arrhythmic medications, such as amiodarone, were also 
significantly associated with an INR above the therapeutic 
range (P , 0.0001).
Siguret and collaborators showed that 69% of overdosing 
cases are associated with antivitamin K-potentiating 
drugs,29 particularly anti-infectious drugs and amiodarone.29 
Antibiotics are commonly used in elderly patients and are 
classically identified as antivitamin K-potentiating drugs.30 
The occurrence of hemorrhage when antivitamin K is 
associated with antibiotics can be explained by the destruction 
of intestinal flora and the decrease in synthesis of vitamin K, 
decrease in metabolism of antivitamin K by enzymatic 
inhibition (fluconazole, itraconazole, and erythromycin), 
or decrease in protein binding (fluoroquinolones).31 
The occurrence of an infectious episode with metabolic 
changes is a risk factor for imbalance of antivitamin K. 
In this case it is not possible to distinguish the part related 
to intercurrent disease and that related to anti-infectious 
drugs.32 Another interaction was seen with analgesics, 
primarily anti-inflammatory drugs (P , 0.0001), as a result 
of their partial inhibition of platelet activation and gastric 
mucosal damage causing increased risks of gastrointestinal 
hemorrhage.33 A third interaction concerning antiplatelet 
agents was found (P = 0.002), especially when aspirin was 
used concomitantly (P = 0.006). No significant associations 
were found with concomitant use of antifungals or with 
statins or paracetamol. Among the four types of drug–drug 
interactions cited previously, only interactions that require 
precaution for use were significantly associated with an 
INR above the therapeutic range (P = 0.026). Two meta-
analyses found a relative risk of major bleeding when AVK 
were combined with aspirin.34,35 A nested case-control study 
confirmed the high risk of upper gastrointestinal bleeding 
in patients using AVK in combination with aspirin and/or 
clopidogrel and reported that acetaminophen was associated 
with excessive warfarin anticoagulation.36 A systemic 
overview of drug interactions with warfarin showed that 
co-administration with antibiotics, nonsteroidal anti-
inflammatory drugs, lipid-lowering agents, and amiodarone 
should either be avoided or closely monitored.37
Signs of bleeding were present in 53% of cases 
(versus 6% of controls; P , 0.0001). One study showed that 
79% of patients with an INR above the therapeutic range 
developed a hemorrhage compared to only 16% of those with 
an INR within the therapeutic range (P , 0.0001).27 The risk 
of bleeding is exacerbated by the intensity of anticoagulation; 
the incidence of major bleeding approximately doubled with 
each INR point.38,39 Each unit increase in INR compared with 
the value of INR , 2 was associated with a 42% increase 
in major bleeding40 and 54% increase of bleeding in 
general.39
In our study, management of patients showing a high 
INR with or without hemorrhagic events included INR 
monitoring, administration of oral vitamin K, interruption of 
AVK therapy, omitting one dose of AVK, and administration 
of fresh frozen plasma even though volume overload may 
make it difficult to administer an adequate fresh frozen 
plasma dose, particularly since these patients often have 
compromised cardiovascular systems.41 Pooled plasma 
products containing factors II, IX, and X with variable 
amounts of factor VII and natural anticoagulant proteins C 
and S were not available at the tertiary care hospital in Beirut 
even though they are recommended when vitamin K fails to 
normalize the INR.42
Under multivariate logistic regression analysis, significant 
factors for high values of INR under AVK treatment were 
as follows: recent infection (P = 0.003), low albumin level 
(P = 0.0005), concomitant use of amiodarone (P = 0.008) or 
aspirin (P = 0.0074), and drug–drug interaction (P = 0.0065). 
Multivariate analysis of another study showed similar 
results that excessive anticoagulation under AVK treatment 
was significantly associated with previous history of 
gastrointestinal hemorrhage (OR = 4.345, P = 0.022), 
fever (OR = 6.018, P = 0.007), recent antibiotic therapy 
(OR = 12.932, P = 0.03), and therapy with amiodarone 
(OR = 3.575, P = 0.022).17
The interpatient and intrapatient variability in dose 
response, the narrow therapeutic index, and the numerous drug 
and dietary interactions associated with these agents have led 
clinicians and investigators to search for alternative agents. 
Three new orally administered anticoagulants (apixaban, 
dabigatran, and rivaroxaban) are now on the market. Apixaban 
and rivaroxaban are specific inhibitors of factor Xa, while 
dabigatran inhibits factor IIa. The predictable pharmacological 
profile of these new agents will allow physicians to use these 
drugs without the need for routine coagulation monitoring, 
which is the mainstay of AVK therapy. In addition, these new 
agents have not been shown to have any food interactions 
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and have limited drug–drug interactions due to their minimal 
metabolism through the CYP450 system.43
Our study is a survey conducted retrospectively and has 
biases related to the method and the study population. The 
majority of our study population had an age greater than 
65 years and was a heterogeneous population with multiple 
pathologies and polypharmacy, making the analysis more 
difficult. This was especially true in cases of dementia where 
the patient was not aware of his/her medical history and 
medications, generating a high number of missing data for the 
collection sheet. Data such as the patient’s diet and patient’s 
compliance, not included in the computerized patient files, 
were not considered in our study, although studies have shown 
a significant association between these two factors and the 
occurrence of hemorrhagic adverse drug events under AVK. 
Further studies that take into account these weak points are 
necessary to confirm our results. Nevertheless, a strong point 
in our study is that the INR, the main criteria for defining a 
case and a control, was measured in the same laboratory, thus 
avoiding measurement biases from different laboratories.
Conclusion
Many factors associated with ADE pertaining to AVK 
are related to the patient, to the treatment itself, or to the 
awareness of health care professionals when prescribing and 
dispensing this type of oral anticoagulant. Some risk factors 
of therapeutic imbalance were identified, including patient’s 
age, intercurrent diseases, drug interactions, and the specific 
dose required for a particular individual to reach appropriate 
INR levels. Close monitoring of INR and its stabilization in 
the therapeutic range is required for any dose modification of 
AVK and acute episodes, including intercurrent infection.
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